156 related articles for article (PubMed ID: 30052596)
1. 18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma.
Heimburger C; Bund C; Addeo P; Goichot B; Imperiale A
Clin Nucl Med; 2018 Sep; 43(9):e324-e325. PubMed ID: 30052596
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDOPA PET Imaging in Prolactinoma.
Ginet M; Cuny T; Schmitt E; Marie PY; Verger A
Clin Nucl Med; 2017 Aug; 42(8):e383-e384. PubMed ID: 28590300
[TBL] [Abstract][Full Text] [Related]
3. Prolactinoma in a Dog.
Cosio C; Sartori E; Garatti M; Luccardini L; Grinwis GCM; Kooistra HS; Fracassi F
Vet Pathol; 2017 Nov; 54(6):972-976. PubMed ID: 28812531
[TBL] [Abstract][Full Text] [Related]
4. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
[TBL] [Abstract][Full Text] [Related]
5. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
Kurosaki M; Kambe A; Watanabe T; Fujii S; Ogawa T
Neurol Res; 2015 Apr; 37(4):341-6. PubMed ID: 25376133
[TBL] [Abstract][Full Text] [Related]
6. Atypical giant prolactinoma with frontal lobe manifestations.
Arshad MF; Arambewela M; Debono M
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30181411
[No Abstract] [Full Text] [Related]
7. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline treatment in a case of macroprolactinoma after delivery.
Falsetti L
Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
[TBL] [Abstract][Full Text] [Related]
9. 68Ga DOTATATE PET/CT of Synchronous Meningioma and Prolactinoma.
Basu S; Ranade R; Hazarika S
Clin Nucl Med; 2016 Mar; 41(3):230-1. PubMed ID: 26462040
[TBL] [Abstract][Full Text] [Related]
10. Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.
Koguchi M; Nakahara Y; Ebashi R; Ogata A; Shimokawa S; Masuoka J; Abe T
J Med Case Rep; 2019 Jan; 13(1):18. PubMed ID: 30660191
[TBL] [Abstract][Full Text] [Related]
11. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
12. Clozapine Treatment for Cabergoline-Induced Psychosis in a Patient With a Giant Prolactinoma.
Pérez-Esparza R; Rojas-Guerrero CA; Andino-Rios GG; Arias-Garro P; Ramírez-Bermúdez J; Portocarrero-Ortiz L
J Neuropsychiatry Clin Neurosci; 2017; 29(3):295-297. PubMed ID: 28238271
[No Abstract] [Full Text] [Related]
13. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
14. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.
Guastamacchia E; Triggiani V; Tafaro E; De Tommasi A; De Tommasi C; Luzzi S; Sabbà C; Resta F; Terreni MR; Losa M
Minerva Endocrinol; 2007 Sep; 32(3):231-6. PubMed ID: 17912159
[TBL] [Abstract][Full Text] [Related]
15. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
16. Sjögren's Syndrome Accompanied by Prolactinoma: a case report and literature review.
Oh YJ; Lee WS; Yoo WH; Hahm JR; Kim HO; Suh YS; Lee SI; Cheon YH
Int J Rheum Dis; 2017 Nov; 20(11):1823-1826. PubMed ID: 26355497
[No Abstract] [Full Text] [Related]
17.
Bashari WA; van der Meulen M; MacFarlane J; Gillett D; Senanayake R; Serban L; Powlson AS; Brooke AM; Scoffings DJ; Jones J; O'Donovan DG; Tysome J; Santarius T; Donnelly N; Boros I; Aigbirhio F; Jefferies S; Cheow HK; Mendichovszky IA; Kolias AG; Mannion R; Koulouri O; Gurnell M
Pituitary; 2022 Aug; 25(4):573-586. PubMed ID: 35608811
[TBL] [Abstract][Full Text] [Related]
18. DRD2 expression based on
Tang H; Cheng Y; Lou X; Yao H; Xie J; Gu W; Huang X; Liu Y; Lin S; Dai Y; Xue L; Lin X; Wu ZB
Endocrine; 2023 May; 80(2):419-424. PubMed ID: 36689171
[TBL] [Abstract][Full Text] [Related]
19. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
20. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
